Purpose: Because the effects of pirarubicin and carboplatin on the physical structure of particles made from polyvinylformaldehyde are not well known, we describe an experiment to test the in vitro polyvinylformaldehyde particle compatibility with these drugs used for chemoembolization of bone metastases.
Materials And Methods: Polyvinylformaldehyde particles (Ultra-Drivalon) were mixed in vitro with either pirarubicin or carboplatin as experimental samples, and with distilled water as control samples, and left for 24 h at 37 degrees C. The particles used measured 150-250 microm and 600-1000 microm in diameter. Particle morphology, including appearance, overall shape, and surface characteristics were examined using a microscope equipped with a videocamera. Particle size was measured by granulometry. Qualitative and quantitative variables were analyzed using, respectively, the two-sided Fisher's exact test and the Wilcoxon signed rank test for paired values, with a significance level of 0.05.
Results: No broken particles or microscopic degradations in the appearance, overall shape, or surface characteristics of any particles were observed. The particle size distribution was not significantly different between the experimental samples containing pirarubicin or carboplatin and the control sample of particles with diameters in the same range.
Conclusion: Particles made from polyvinylformaldehyde can be mixed with pirarubicin or carboplatin without any risk of damaging their physical properties.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00270-003-0027-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN-H-11.
Pediatr Blood Cancer
June 2024
The Japan Children's Cancer Group (JCCG) Neuroblastoma Committee (JNBSG), Nagoya, Japan.
Article Synopsis
- This clinical trial aimed to assess the safety and effectiveness of a time-intensified treatment strategy for high-risk neuroblastoma, involving delayed local surgery following aggressive chemotherapy.
- Seventy-five patients were enrolled, with a 3-year progression-free survival rate of 44.4% and an overall survival rate of 80.7%, indicating a significant response to therapy without any deaths during treatment.
- However, there were high rates of adverse effects, with 48% experiencing severe complications and 25% facing major surgical issues, suggesting more research is needed to confirm findings and improve safety.
[A Case of Non-Hodgkin Lymphoma with Liver Involvement and Severe Jaundice That Benefited from Therapy with Gemcitabine, Carboplatin, Dexamethasone(GCD)Therapy with Rituximab].
Gan To Kagaku Ryoho
November 2023
Dept. of Hematology, Shin-Koga Hospital.
An 84-year-old man visited a hospital owing to general malaise. Blood tests revealed hyperbilirubinemia and liver dysfunction. The patient was hospitalized and underwent various examinations.
View Article and Find Full Text PDFIndividualized chemotherapy and efficacy analysis of hepatoblastoma in children.
Pediatr Blood Cancer
January 2024
Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Article Synopsis
- The study evaluated the effectiveness of a mini patient-derived xenograft (MiniPDX) model in finding tailored chemotherapy treatments for children with hepatoblastoma who showed inadequate response to standard treatments.
- A total of 31 pediatric patients’ tumors were used to test different chemotherapy regimens, with the goal of selecting those that resulted in the lowest tumor growth rates.
- Results showed the MiniPDX-guided chemotherapy led to an 80.64% complete remission rate and significantly better survival outcomes, especially in advanced stage cases, compared to traditional chemotherapy methods.
Case Analysis of 14 Children with Malignant Rhabdoid Tumor of the Kidney.
Cancer Manag Res
June 2021
Department of Pediatrics, Beijing Tongren Hospital of China Capital Medical University, Beijing, 100176, People's Republic of China.
Objective: This study aims to summarize the clinical features and prognoses of the malignant rhabdoid tumor of the kidney (MRTK) in children. It further aims to analyze the high-risk factors affecting MRTK prognosis.
Methods: Clinical data from 14 children with MRTK treated in Paediatrics of Beijing Tongren Hospital from January 2010 to December 2019, along with the high-risk factors affecting prognosis, were retrospectively analyzed.
Outcome and Late Complications of Hepatoblastomas Treated Using the Japanese Study Group for Pediatric Liver Tumor 2 Protocol.
J Clin Oncol
August 2020
Center for Integrated Medical Research, Hiroshima University Hospital, Hiroshima, Japan.
Purpose: We report here the outcomes and late effects of the Japanese Study Group for Pediatric Liver Tumors (JPLT)-2 protocol, on the basis of cisplatin-tetrahydropyranyl-adriamycin (CITA) with risk stratification according to the pretreatment extent of disease (PRETEXT) classification for hepatoblastoma (HB).
Patients And Methods: From 1999 to 2012, 361 patients with untreated HB were enrolled. PRETEXT I/II patients were treated with up-front resection, followed by low-dose CITA (stratum 1) or received low-dose CITA, followed by surgery and postoperative chemotherapy (stratum 2).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!